Table of Content

1. PREFACE
1.1. Next Generation Drug Conjugates Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Next Generation Drug Conjugates
3.2. Key Historical Events
3.3. Structure of Next Generation Drug Conjugates
3.4. Biochemical Interaction and Mechanism of Action
3.5. Key Target Indications
3.6. Advantages of Next Generation Drug Conjugates
3.7 Challenges associated with Next Generation Drug Conjugates
3.8. Future Perspectives

4. MARKET LANDSCAPE
4.1. Methodology
4.2. Next Generation Drug Conjugates: List of Therapies
4.2.1. Analysis by Type of Conjugate
4.2.2. Analysis by Type of Targeting Ligand
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Stage of Development
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Target Population
4.2.13. Analysis by Type of Conjugate and Stage of Development
4.2.14. Analysis by Type of Conjugate and Target Populatio
4.3 Next Generation Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.3.6. Most Active Players: Analysis by Number of Drug Candidates

5. COMPANY AND DRUG PROFILES
5.1. Advanced Accelerator Applications
5.1.1. Company Overview
5.1.2. Management Team
5.1.3. Product Portfolio
5.1.3.1. Lutathera?
5.1.3.1.1 Drug Overview
5.1.3.1.2. Clinical Trial Information
5.1.3.1.3. Clinical Trial Results
5.1.3.1.4. Dosing Regimen
5.1.3.1.5. Estimated Sales
5.1.3.2. Pluvicto?
5.1.3.2.1 Drug Overview
5.1.3.2.2. Clinical Trial Information
5.1.3.2.3. Clinical Trial Results
5.1.3.2.4. Dosing Regimen
5.1.3.2.5. Estimated Sales
5.1.4. Recent Developments and Future Outlook
5.2. Alnylam Pharmaceuticals
5.2.1. Company Overview
5.2.2. Management Team
5.2.3. Product Portfolio
5.2.3.1. Givlaari?
5.2.3.1.1. Drug Overview
5.2.3.1.2. Clinical Trial Information
5.2.3.1.3. Clinical Trial Results
5.2.4.1.4. Dosing Regimen
5.2.3.2. Oxlumo?
5.2.3.2.1. Drug Overview
5.2.3.2.2. Clinical Trial Information
5.2.3.2.3. Clinical Trial Results
5.2.3.2.4. Dosing Regimen
5.2.3.3. Leqvio?
5.2.3.3.1. Drug Overview
5.2.3.3.2. Clinical Trial Information
5.2.3.3.3. Clinical Trial Results
5.2.3.3.4. Dosing Regimen
5.2.3.4. Amvuttra?
5.2.3.4.1. Drug Overview
5.2.3.4.2. Clinical Trial Information
5.2.3.4.3. Clinical Trial Results
5.2.3.4.4. Dosing Regimen
5.2.4. Recent Developments and Future Outlook
5.3. Arrowhead Pharmaceuticals
5.3.1. Company Overview
5.3.2. Management Team
5.3.3. Product Portfolio
5.3.3.1. Olpasiran
5.3.3.1.1. Drug Overview
5.3.3.1.2. Clinical Trial Information
5.3.3.1.3. Clinical Trial Results
5.3.3.1.4. Dosing Regimen
5.3.3.2. ARO-AAT
5.3.3.2.1. Drug Overview
5.3.3.2.2. Clinical Trial Information
5.3.3.2.3. Clinical Trial Results
5.3.3.2.4. Dosing Regimen
5.3.3.3. ARO-APOC3
5.3.3.3.1. Drug Overview
5.3.3.3.2. Clinical Trial Information
5.3.3.3.3. Clinical Trial Results
5.3.3.3.4. Dosing Regimen
5.3.4. Recent Developments and Future Outlook
5.4. Dicerna Pharmaceuticals
5.4.1. Company Overview
5.4.2. Management Team
5.4.3. Product Portfolio
5.4.3.1. Nedosiran
5.4.3.1.1 Drug Overview
5.4.3.1.2. Clinical Trial Information
5.4.3.1.3. Clinical Trial Results
5.4.3.1.4. Dosing Regimen
5.4.4. Recent Developments and Future Outlook
5.5. Geron
5.5.1. Company Overview
5.5.2. Management Team
5.5.3. Product Portfolio
5.5.3.1. Imtelstat
5.5.3.1.1. Drug Overview
5.5.3.1.2. Clinical Trial Information
5.5.3.1.3. Clinical Trial Results
5.5.3.1.4. Dosing Regimen
5.5.4. Recent Developments and Future Outlook
5.6. Ionis Pharmaceuticals
5.6.1. Company Overview
5.6.2. Management Team
5.6.3. Product Portfolio
5.6.3.1. Eplontersen
5.6.3.1.1 Drug Overview
5.6.3.1.2. Clinical Trial Information
5.6.3.1.3. Clinical Trial Results
5.6.3.1.4. Dosing Regimen
5.6.3.2. Olezarsen
5.6.3.2.1. Drug Overview
5.6.3.2.2. Clinical Trial Information
5.6.3.2.3. Clinical Trial Results
5.6.3.2.4. Dosing Regimen
5.6.3.3. Pelacarsen
5.6.3.3.1. Drug Overview
5.6.3.3.2. Clinical Trial Information
5.6.3.3.3. Clinical Trial Results
5.6.3.3.4. Dosing Regimen
5.6.3.3.5. Estimated Sales
5.6.3.4. Donidalorsen
5.6.3.4.1 Drug Overview
5.6.3.4.2. Clinical Trial Information
5.6.3.4.3. Clinical Trial Results
5.6.3.4.4. Dosing Regimen
5.6.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
6.2.1. Analysis by Trial Registration Year
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Status
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Primary Purpose
6.2.6. Analysis by Age Group
6.2.7. Analysis by Type of Sponsor
6.2.8. Most Active Industry Players: Analysis by Number of Trials
6.2.9. Leading Drug Candidates: Analysis by Number of Trials
6.2.10. Analysis by Trial Registration Year and Trial Location
6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.12. Analysis by Trial Phase and Enrolled Patient Population
6.2.13. Analysis by Trial Status and Enrolled Patient Population
6.2.14. Analysis by Trial Location and Enrolled Patient Population
6.2.15. Analysis by Trial Status and Trial Location

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Partnership Models
7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Analysis by Type of Partner and Parent Company Size
7.3.8. Analysis by Therapeutic Area
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.3.10. Analysis by Geography
7.3.10.1. Analysis by Type of Geography (Region-wise)
7.3.10.2. Analysis by Type of Geography (Country-wise)
7.3.10.3. Intercontinental and Intracontinental Agreements
8. ACADEMIC GRANTS ANALYSIS
8.1. Methodology and Key Parameters
8.2. Next Generation Drug Conjugates: Academic Grants Analysis
8.2.1. Analysis by Year of Grant Award
8.2.2. Analysis by Amount Awarded
8.2.3. Analysis by Funding Institute Center
8.2.4. Analysis by Support Period
8.2.5. Analysis by Funding Institute Center and Support Period
8.2.6. Analysis by Type of Grant Application
8.2.7. Analysis by Purpose of Grant
8.2.8. Analysis by Activity Code
8.2.9. Analysis by Study Section
8.2.10. Popular NIH Departments: Analysis by Number of Grants
8.2.11. Analysis by Type of Recipient Organization
8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
8.2.12. Prominent Program Officers: Analysis by Number of Grants
8.2.13 Analysis by Location of Recipient Organizations
9. PUBLICATION ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Publication Analysis
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Analysis by Type of Conjugate
9.2.4. Analysis by Target Indication
9.2.5. Analysis by Copyright Holder
9.2.6. Word Cloud: Emerging Focus Area
9.2.7. Most Active Publishers: Analysis by Number of Publications
9.2.8. Key Journals: Analysis by Number of Publications
9.2.9. Key Journals: Analysis by Impact Factor
10. DRUG FAILURE ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Next Generation Drug Conjugates: Drug Failure Analysis
10.2.1. Analysis by Status of Discontinuation
10.2.2. Analysis by Phase of Discontinuation
10.2.3. Analysis by Average Trial Year
10.2.4. Analysis by Type of Therapy
10.2.5. Analysis by Target Indication
10.2.6. Analysis by Reason for Drug Failure

11. SUCCESS PROTOCOL ANALYSIS
11.1. Methodology and Key Parameters
11.2. Key Assumptions and Scoring Criteria
11.3. Success Protocol Analysis
11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
12.2.2.1 Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
12.2.2.2 Next Generation Drug Conjugates Market for Peptides, 2023-2035
12.2.2.3 Next Generation Drug Conjugates Market for Lipids, 2023-2035
12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
12.2.3.4 Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035
12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035
12.2.6.3. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, 2023-2035
12.2.6.4. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035
12.2.6.5. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035
12.2.6.6. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035
12.2.6.7. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035
12.2.6.8. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035
12.2.5.9. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035
12.2.5.10. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035
12.2.5.11. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035
12.2.5.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035
12.2.5.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035
12.2.5.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035
12.2.5.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market in North America, 2023-2035
12.2.6.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
12.2.6.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
12.2.6.2. Next Generation Drug Conjugates Market in Europe, 2023-2035
12.2.6.2.1. Next Generation Drug Conjugates Market in the UK, 2022-2035
12.2.6.2.2. Next Generation Drug Conjugates Market in France, 2022-2035
12.2.6.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
12.2.6.2.4. Next Generation Drug Conjugates Market in Spain, 2022-2035
12.2.6.2.5. Next Generation Drug Conjugates Market in Italy, 2022-2035
12.2.6.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
12.2.6.3. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035
12.2.6.3.1. Next Generation Drug Conjugates Market in Japan, 2023-2035
12.2.6.3.2. Next Generation Drug Conjugates Market in Australia, 2023-2035
12.2.6.3.3. Next Generation Drug Conjugates Market in Brazil, 2023-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
12.3.1. Lutathera?
12.3.1.1. Sales Forecast (USD Million)
12.3.1.2. Net Present Value (USD Million)
12.3.1.3. Value Creation Analysis
12.3.2. Pluvicto?
12.3.2.1. Sales Forecast (USD Million)
12.3.2.2. Net Present Value (USD Million)
12.3.2.3. Value Creation Analysis
12.3.3. Givlaari?
12.3.3.1. Sales Forecast (USD Million)
12.3.3.2. Net Present Value (USD Million)
12.3.3.3. Value Creation Analysis
12.3.4. Oxlumo?
12.3.4.1. Sales Forecast (USD Million)
12.3.4.2. Net Present Value (USD Million)
12.3.4.3. Value Creation Analysis
12.3.5. Leqvio?
12.3.5.1. Sales Forecast (USD Million)
12.3.5.2. Net Present Value (USD Million)
12.3.5.3. Value Creation Analysis
12.3.6. Amvuttra?
12.3.6.1. Sales Forecast (USD Million)
12.3.6.2. Net Present Value (USD Million)
12.3.6.3. Value Creation Analysis
12.3.7. Eplontersen
12.3.7.1. Sales Forecast (USD Million)
12.3.7.2. Net Present Value (USD Million)
12.3.7.3. Value Creation Analysis
12.3.8. Olezarsen
12.3.8.1. Sales Forecast (USD Million)
12.3.8.2. Net Present Value (USD Million)
12.3.8.3. Value Creation Analysis
12.3.9. Pelacarsen
12.3.9.1. Sales Forecast (USD Million)
12.3.9.2. Net Present Value (USD Million)
12.3.9.3. Value Creation Analysis
12.3.10. Donidalorsen
12.3.10.1. Sales Forecast (USD Million)
12.3.10.2. Net Present Value (USD Million)
12.3.10.3. Value Creation Analysis
12.3.11. Fitusiran
12.3.11.1. Sales Forecast (USD Million)
12.3.11.2. Net Present Value (USD Million)
12.3.11.3. Value Creation Analysis
12.3.12. Nedosiran
12.3.12.1. Sales Forecast (USD Million)
12.3.12.2. Net Present Value (USD Million)
12.3.12.3. Value Creation Analysis
12.3.13. Imetlestat
12.3.13.1. Sales Forecast (USD Million)
12.3.13.2. Net Present Value (USD Million)
12.3.13.3. Value Creation Analysis
12.3.14. Olpasiran
12.3.14.1. Sales Forecast (USD Million)
12.3.14.2. Net Present Value (USD Million)
12.3.14.3. Value Creation Analysis
12.3.15. ARO-AAT
12.3.15.1. Sales Forecast (USD Million)
12.3.15.2. Net Present Value (USD Million)
12.3.15.3. Value Creation Analysis
12.3.16. ARO-APOC3
12.3.16.1. Sales Forecast (USD Million)
12.3.16.2. Net Present Value (USD Million)
12.3.16.3. Value Creation Analysis
12.3.17. ANG-1005
12.3.17.1. Sales Forecast (USD Million)
12.3.17.2. Net Present Value (USD Million)
12.3.17.3. Value Creation Analysis
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS